Copyright © Fidelis Security. All rights reserved.
-
Privacy PolicyPrivacy Policy
-
Terms of ServiceTerms of Service
-
Trust CenterTrust Center
-
SecuritySecurity
See why most of the Enterprises and Government Agencies rely on Fidelis Security for their Cybersecurity posture management against advanced adversaries!
Lyell Immunopharma is a South San Francisco-based, publicly traded cell therapy company (LYEL). Their T cell reprogramming technology focuses on the mastery of T cells to cure patients with solid tumors. They apply proprietary genetic and epigenetic reprogramming technology platforms to address barriers present in solid tumors in order to develop new medicines with improved, durable, and potentially curative clinical outcomes.
This case study discovers how the top 5 global bank...
Read Case Study“Fidelis Deception® takes our network security to the next level,” the Hospital’s,...
Read Case Study“If you don’t see bad stuff in your network, you’re...
Read Case Study“With Fidelis Deception®, we’re changing the rules of the game. Now...
Read Case StudyExplore how Fidelis Deception secures a Chicago-based $180 billion Financial...
Read Case StudyExplore how Lauda, the world leader in temperature control, partnered...
Read Case StudyA leading telecom company fortified its cyber defenses with Fidelis...
Read Case StudyDiscover how Lyell Immunopharma, a leading cell therapy company secures...
Read Case StudyJoin our newsletter to stay up to date on features and releases.